Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NPC-15 QTc prolongation study in healthy adults
NCT03475459Phase 1Completed
- Sponsor
- Nobelpharma Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Apr 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of melatonin in sleep disorder, sponsored by Nobelpharma Co., Ltd. Primary endpoint: Fridericia-corrected QTc interval at Day 2. Started Apr 2018; status: completed.
02
Drugs
melatonin
03
Conditions
sleep disorder
Beyond the preview
Go deeper on NCT03475459.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03475459.